follow up :
Verisante Technology, Inc. Issues Operational Update; Beta Units in Clinics Across Canada, Distribution Sales Force Being Trained
Verisante Technology, Inc. (TSX VENTURE: VRS)(OTCQX: VRSEF)(FRANKFURT: V3T) (the "Company" or "Verisante"), a leader in cancer detection technology, today issued an operational update on the commercialization of Verisante's Aura(TM), the innovative skin cancer detection device.
Installations of Beta Units have been completed at five leading dermatology clinics across Canada in Vancouver, Edmonton, Calgary, Oakville, Montreal and Markham. The Company continues to collect data from all sites for software verification purposes and has received valuable usability feedback.
In conjunction with the installations, the Company has completed technical training with Clarion Medical, the Company's exclusive Canadian distributor. Clarion's expert technicians will be responsible for the servicing of Aura(TM) in the field. Verisante also continues to work closely with Clarion and Bo-Pharma, the Company's Benelux distributor, to train sales staff and provide sales and marketing materials in preparation for product launch.
"Verisante has made great strides this year as we move closer towards full production and prepare to launch Aura(TM) in Canada and Europe," said Thomas Braun, President and CEO. "I am pleased with the recent media attention. And we continue to receive excellent feedback from both dermatologists and the general medical community as we look forward to making this life-saving technology available to healthcare professionals and their patients."
Read more at http://www.stockhouse.com/bullboards/messagedetail.aspx?p=0&m=31752978&l=0&r=0&s=VRS&t=LIST#Ew0O3oscV2GY6rTB.99 |
